Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib

Area of Science:

• Oncology
• Pharmacology
• Computational Biology

Background:

• Chemotherapy is a primary treatment for multiple myeloma (MM), but its effectiveness is limited by tumor heterogeneity and drug resistance.
• Single-target drugs often fail against complex cancers like MM, necessitating the development of multi-target therapeutic strategies.

Purpose of the Study:

• To identify and evaluate novel multi-target drugs for multiple myeloma (MM).
• To investigate the dual inhibition of poly(ADP-ribose) polymerase 1 (PARP1) and the 20S proteasome as a therapeutic strategy for MM.

Main Methods:

• Computer-aided drug discovery (CADD) was employed to screen for inhibitors targeting both PARP1 and the 20S proteasome.
• Molecular dynamics (MD) simulations were used to analyze the binding interactions and stability of candidate inhibitors with the proteasome.
• In vitro and in vivo experiments assessed the dual-target inhibition, anti-cancer efficacy, and tumor-killing capabilities of fluzoparib.

Main Results:

• Fluzoparib was identified as a novel inhibitor with the potential for dual-target inhibition against PARP1 and the 20S proteasome.
• Molecular simulations confirmed the binding mode and dynamic stability of fluzoparib to the proteasome.
• Fluzoparib demonstrated significant anti-myeloma activity at enzymatic, cellular, and animal model levels.

Conclusions:

• Fluzoparib represents a promising novel therapeutic agent for multiple myeloma, offering a dual-target inhibition mechanism.
• This study provides a strong foundation for developing multi-target drugs against various cancers, addressing limitations of current single-target therapies.